We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Perilla frutescens Extracts Protects against Dextran Sulfate Sodium-Induced Murine Colitis: NF-kB, STAT3, and Nrf2 as Putative Targets.
- Authors
Deung Dae Park; Hye-Won Yum; Xiancai Zhong; Seung Hyeon Kim; Seong Hoon Kim; Do-Hee Kim; Su-Jung Kim; Hye-Kyung Na; Atsuya Sato; Takehito Miura; Young-Joon Surh
- Abstract
Perilla frutescens is a culinary and medicinal herb which has a strong anti-inflammatory and antioxidative effects. In the present study, we investigated the effects of Perilla frutescens extract (PE) against dextran sulfate sodium (DSS)-induced mouse colitis, an animal model that mimics human inflammatory bowel disease (IBD). Five-week-old male ICR mice were treated with a daily dose of PE (20 or 100 mg/kg, p.o.) for 1 week, followed by administration of 3% DSS in double distilled drinking water and PE by gavage for another week. DSS-induced colitis was characterized by body weight loss, colon length shortening, diarrhea and bloody stool, and these symptoms were significantly ameliorated by PE treatment. PE administration suppressed DSS-induced expression of proinflammatory enzymes, including cyclooxygenase-2 and inducible nitric oxide synthase as well as cyclin D1; in a dose-dependent fashion. Nuclear factor-kappa B (NF-κB) and signal transducer and activator of transcription 3 (STAT3) are major transcriptional regulators of inflammatory signaling. PE administration significantly inhibited the activation of both NF-κB and STAT3 induced by DSS, while it elevated the accumulation of Nrf2 and heme oxygenase-1 in the colon. In another experiment, treatment of CCD841CoN human normal colon epithelial cells with PE (10 mg/ml) resulted in the attenuation of the tumor necrosis factor-α-induced expression/activation of mediators of proinflammatory signaling. The above results indicate that PE has a preventive potential for use in the management of IBD.
- Subjects
PERILLA frutescens; DEXTRAN sulfate; INTESTINAL diseases
- Publication
Frontiers in Pharmacology, 2017, p1
- ISSN
1663-9812
- Publication type
Article
- DOI
10.3389/fphar.2017.00482